Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic LeukemiaWilliam G. Wierda, Anders Österborg, Joris Wilms et al.|Journal of Clinical Oncology|2010Cited by 587
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup studyChristiane Pott, Martin Dreyling, Eva Hoster et al.|Blood|2009Cited by 269
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)Michele Ghielmini, Markus Raderer, Umberto Vitolo et al.|Annals of Oncology|2012Cited by 218
Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma NetworkEva Hoster, Michael Unterhalt, Wolfgang Hiddemann et al.|Journal of Clinical Oncology|2014Cited by 164
Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly TrialHanneke C. Kluin‐Nelemans, Martin Dreyling, Eva Hoster et al.|Journal of Clinical Oncology|2019Cited by 143